Searched for
LEENA MENGHANEY
Quick access to key HIV drug hinges on waiver of local clinical trials: ExpertsFaster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, ha...- Centre has not banned export of any COVID-19 vaccine: Union health secretaryResponding to a question during a press briefing on Tuesday, Union Health Secretary Rajesh Bushan said, "The Union government has not banne...
- International civil groups back India’s move on TRIPS waiver for Covid cureLeena Menghaney, a lawyer with MSF India, told ET that it is critical for governments to address this global crisis as they did nearly 20 y...
- India and South Africa demand waiver of certain provisions of Intellectual Property for Covid-19 therapeuticsThis statement comes at a time when the race for Covid-19 vaccine is heating up across the world. Though most vaccine makers have received ...
- US exit may hit WHO’s India workThe US is the largest donor to the WHO with a contribution of $400 million in 2018-19. WHO India’s country budget was reported to be a litt...
- Remdesivir use may be managed by governmentThe recommendations come as four Indian drug companies, Cipla, Hetero, Mylan and Jubilant, gear up to get an approval for the drug in the t...
- BDR Pharmaceuticals move on Remdesivir clone irks GileadThe Indian company had submitted its application for manufacturing the Covid-19 drug to the Drug Controller General of India (DCGI) last we...
- Dilemma for doctors as Roche’s experimental drug for Covid-19 is ‘life-saver’ but too costlyIn India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for si...
- Otsuka licenses Mylan subsidiary to bring MDR TB drug delamanid to IndiaMDR TB is on the rise in India which, together with China and Russia, accounts for over half of these cases worldwide, according to a recen...
- Indian drug regulator may scrap licence renewal; move may affect quality of medicinesThe licences and approvals can be made perpetual provided they are not cancelled or suspended by the licencing authority, according to the ...
- MSF and Pfizer battle over patent application for life-saving pneumonia vaccineMSF filed declarations at the Delhi patent office to point out that Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13) was obvious a...
- Whistleblower raises questions on DCGI, drug regulatory systemIn a writ petition filed at the Supreme Court of India, Thakur has sued the health ministry , Central Drugs Standard Control Organisation .
- Drug prices to rise slightly on removal of duty reliefThe government’s move to withdraw customs duty exemption on imports of 76 life-saving drugs will have minimal impact on patients, according...
- NDA fund cuts put healthcare on the sickbedThe government's healthcare outlay is stagnant at around Rs 33,000 crore and has not translated to the increase from 1.2% of GDP to 2-2.5%
- Pharma companies feel law change can weaken ability to provide low-cost drugsIndian drugmakers are also concerned about a shift in India’s position on IPR, which they say is being keenly watched by many developing co...
- Hospitals face HIV testing kits' shortageThe reason for the shortage is not a paucity of funds but delay by the NACO in placing tenders for procurement, experts said.
- Indian pharma sector fears India-European Union FTA could imperil local industryDrugmakers are worried that the India-EU FTA, which is in the works, may contain a provision that could imperil local industry.
- IPAB's verdict on Roche's Hepatitis C drug patent may impact MerckThe IPAB revoked Roche's patent for Pegasys on grounds that the process of pegylation did not enhance the efficacy of the drug.
- Bristol-Myers patent plea for HIV drug rejectedIndia has rejected American drugmaker Bristol-Myers Squibb's (BMS) patent application for one of its HIV drugs, allowing local drugmakers t...
- Protest over govt-funded pharma R&D incentive BillGovt’s plan to boost research and development using public funds has raised sharp reactions from public interest groups on the commercial r...
Load More
